The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 3, 2003, Pages

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

blocker; Acute myocardial infarction; Angiotensin converting enzyme inhibitor; Antiplatelet therapy; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE; HEART PROTECTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MEDICAL DOCUMENTATION; MORTALITY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RECURRENT DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ANTILIPEMIC AGENTS; CONTINUITY OF PATIENT CARE; CORONARY ARTERIOSCLEROSIS; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TIME FACTORS;

EID: 0141840655     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Smith SCJ, Blair SN, Bono RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation. 2001;104:1577-1579.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2002;106:1893-1900.
3. Adult Treatment Panel III. Executive summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
4. Yusuf S, Peto R, Lewis J, et al. Beta blocker during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
5. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37:1757-1764.
6. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-629.
7. Fonarow GC, French WJ, Parsons LS, et al, for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.
8. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
9. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160:459-467.
10. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056-2063.
11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J. 2001;22:554-572.
12. Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-3023.
13. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation. 2002;105:2605-2610.
14. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
15. Fonarow GC. Stalin therapy after acute myocardial infarction: are we adequately treating high risk patients? Curr Athero Report. 2002;4:99-106.
16. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, TX: American Heart Association, 2002.
17. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3.
18. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
20. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
21. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
23. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10A-17A.
24. Ellerbeck EF, Jencks SF, Radford MJ, et al, for the Cooperative Cardiovascular Project. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study. JAMA. 1995;273:1509-1514.
25. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068.
26. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436.
27. 27th Bethesda Conference. Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. J Am Coll Cardiol. 1996;27:957-1047.
28. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
29. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001;103:2768-2770.
30. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol. 2001;87:819-822.
31. Fonarow GC, Gawlinski A, Watson KA, Moughrabi S. Sustained Improvement in the treatment of Cardiovascular Hospitalization Atherosclerosis Management Program: CHAMP. Circulation. 2001;104:II-711.
32. Cannon CP, McCabe CH, Bentley J, et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI-16, J Am Coll Cardiol. 2001;35:334A.
33. Pearson RR, Horne BD, Maycock CA, et al. An institutional discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 43,841 patients with coronary artery disease. J Am Coll Cardiol. 2002;39:452A.
34. McCarthy M. US heart-guidelines program makes a promising start. Lancet. 2001;358:1618.
35. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-1276.
36. Debusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721-729.
37. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol. 2000;35:1801-1807.
38. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
39. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712-718.